Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal

Lorenzo Gervaso, Stefania Pellicori, Chiara A. Cella, Vincenzo Bagnardi, Florian Lordick* and Nicola Fazio*

Abstract: Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operative treatment. Biomarkers such as human epidermal growth factor receptor-2 (HER2), microsatellite instability (MSI), and Epstein-Barr Virus (EBV) have been widely studied; however, they do not yet guide the choice of perioperative treatment in clinical practice. We performed a narrative review, including 23 studies, addressing the value of tissue- or blood-based biomarkers in the neoadjuvant setting. Ten studies (43.5%) were prospective, and more than half were conducted in East-Asia. Biomarkers were evaluated only post-NAC (on surgical samples or blood) in seven studies (30.4%), only pre-NAC (on endoscopic specimens or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Among the high variety of investigated biomarkers, some of these including MSI-H or enzymatic profile (as TS, UGT1A1, MTHFR, ERCC or XRCC) showed promising results and deserve to be assessed in methodologically sound clinical trials. The identification of molecular biomarkers in patients treated with NAC for locally advanced resectable gastric or EGJ cancer remains crucial.

Keywords: biomarkers, gastric cancer, neoadjuvant chemotherapy, predictive factors, prognostic factors

Received: 16 January 2021; revised manuscript accepted: 11 June 2021.

Introduction
Patients with gastric cancer, including those with adenocarcinoma of the esophagogastric junction (EGJ) treated with curative intent, have a poor prognosis with 5-year survival rates varying between 30% and 40%. Relapse-related death remains a major challenge for curative treatment. Several strategies have evolved to improve survival, such as adjuvant systemic chemotherapy, typically used in Asian countries, peri-operative chemotherapy, mainly used in European countries and, adjuvant chemoradiation, historically preferred in North America. In particular, throughout the last decade, perioperative chemotherapy significantly improved the prognosis of patients with resectable gastric cancer, becoming the standard of care in Caucasian patients with resectable locally advanced disease. Perioperative (neo-adjuvant + adjuvant) rather than preoperative (just neo-adjuvant) therapy represents the standard treatment for locally advanced gastric cancer (LAGC) based on the results of the MAGIC and FFCD trials.1,2 Recently, the taxane-containing FLOT [docetaxel, oxaliplatin, leucovorin and 5-fluorouracil (5-FU) regimen] showed superiority over ECF (epirubicin, cisplatin, and 5-FU, as applied in the MAGIC study) in terms of histological response, relapse-free survival, and overall survival.3 The
greatest benefit from perioperative chemotherapy seems to come from the pre-operative part (neoadjuvant chemotherapy (NAC)) since, even in the AIO-FLOT4 trial, less than half of the study population completed the post-operative treatment as planned by protocol. Similar results come from the SAKK 43/99 trial, which compared pre- and post-operative taxane-containing chemotherapy for resectable gastric cancer. This trial also found a higher proportion of patients able to complete the chemotherapy treatment in the pre-operative arm (94% versus 66%).

In any case, despite this important progress, relapse of the disease is still observed in a significant proportion of patients, often with a fatal outcome due to metastatic spread. Therefore, it appears crucial to understand which patients will benefit from NAC, based on reliable predictive factors, in order to personalize the therapeutic approach. Currently, no molecular marker has been shown to guide systemic treatment in the peri-operative setting. Data correlating the clinical outcome with molecular characteristics in patients receiving chemotherapy are scarce and are mainly based on The Cancer Genome Atlas (TCGA) four molecular-defined subtypes (Epstein–Barr virus (EBV)-positive subtype, microsatellite unstable subtype (MSI), genomically stable (GS) subtype, and chromosomal instability subtype (CIN)).

Prognostic and predictive factors are essential for personalized medicine; several clinical and tumor characteristics may identify patients with a poor prognosis, irrespective of the received treatment. Prognostic factors can be identified from logistic regression analyses and can be used to stratify patients for treatment allocation and, on the long run, create risk assessment models or nomograms. Predictive factors indicate patient subgroups which could benefit from a specific treatment over the other. However, besides well-known histological parameters, such as pathological tumor-node-metastasis (pTNM) stage, no further molecular analyses are used thus far to stratify the role for chemotherapy in the perioperative setting of gastric and EGJ cancer. MSI and EBV status have been widely studied, but evidence is still heterogeneous and hardly applicable to clinical practice. In addition, the majority of data derived from surgical specimens, often pre-treated with NAC. Ideally, to assess the predictive value of a biomarker to a specific NAC, it should be determined from material obtained before the treatment. Moreover, even for the prognostic value, post-operative samples may not accurately reflect the original biology of the tumor, due to the impact of treatment itself. Therefore, due to these potential biases, we performed a literature reappraisal about biomarkers evaluation in radically resectable gastric and EGJ cancers. The aim of our critical review was to verify the lines of investigation on this topic, with aspects of consistency and controversy, and to discuss the most promising ones according to their future clinical application.

Methods
Leaving aside the rigorous criteria of a systematic review, we searched Pubmed, Embase, and Cochrane Library Databases updated to July 2020 for all the potentially relevant publications. The key search terms were ‘biomarkers’ AND ‘gastric cancer’ OR ‘stomach cancer’ OR ‘gastroesophageal cancer’ OR ‘esophagogastrectomy cancer’ AND ‘neoadjuvant chemotherapy’. Narrowing the selection to English language papers, 143 articles were identified. Among these, we selected studies which included patients with radically resected locally advanced gastric cancer receiving NAC and that analyzed tumor tissue or circulating molecular biomarkers. In addition, studies including some patients with potentially resectable stage IV gastric cancer were also included, if they reported subgroups analysis based on stage (e.g. stage I–III versus IV). Studies assessing exclusively post-operative treatment or metastatic gastric cancer were excluded. According to this strategy, we selected 42 articles, that have been carefully evaluated and, lastly, 23 of them fulfilled our criteria. We arbitrarily included results with the highest potential clinical implications and/or the easiest reproducibility along with clinical practice. High quality data from established international research groups and results consistent with known literature background have been primarily selected. We extracted information from each eligible study, including first author, publication year, country, type of study, source of the biomarker (tissue or blood), timing of evaluation (pre-NAC EGDS or post-NAC surgery), clinical features including stage, histotype and tumor location, chemotherapy regimens, HER2 status, and clinical outcomes. Due to the descriptive intent of the paper, we did not perform any direct correlation with clinical outcomes.
Results

Eligible studies and their characteristics
Twenty-three articles were selected and included in our review.12–33 These studies were published between 2006 and 2020, properly reflecting the current clinical scenario. Ten studies (43.5%) were prospective, whereas 13 were retrospective. Concerning geographical area, more than half of the studies (13/23, 56.5%) were conducted in East Asian countries. Patient characteristics were balanced between studies in term of age, gender, and clinical tumor characteristics. Only five studies (21.7%) reported information on the HER2 status of the tumor. Chemotherapy regimens were various, although all studies used fluoropyrimidines as a kind of backbone, combined with other drugs such as oxaliplatin, cisplatin, or taxanes. Patients were treated with tegafur/gimeracil/oteracil (S-1) in eight studies (34.8%) reflecting the current Asian standard of care in this setting. One study included a combined approach with chemoradiation and another one with intra-arterial chemotherapy. All the main characteristics of the population enrolled in the selected studies are reported in Table 1.12–33

Biomarkers
All publications included in the final selection reported the determination of a molecular biomarkers in locally advanced gastric and EGJ cancer patients undergoing NAC. In detail, biomarkers analyzed, samples type, and outcomes are shown in Table 2.12–33

For what concern the timing of the determination, biomarker analyses were performed exclusively post-NAC (on surgical specimens or blood) in seven studies (30.4%), only pre-NAC (on endoscopic biopsies or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Twelve studies of the total (52.2%) analyzed tissue biomarkers12,8,16,18–20,26,28–31,33 four studies performed the determination on the endoscopic biopsy and the surgical sample, other four only on the endoscopic biopsy and the last four just on surgical specimen. Ten studies (43.5%) looked at circulating biomarkers,13–15,17,21,22,24,25,27,32 in the vast majority assessed pre-NAC (80%, 8/10). Only one examined both circulating and tissue biomarkers, but exclusively on samples obtained post-NAC.25 Among circulating biomarkers, lymphocyte ratio or neutrophil/platelet to lymphocyte ratio were the most frequently analyzed parameters (3/10).15,17,21 On tissue sample, MMR/MSI status was the most examined one (3/12).12,18,33 two studies, assessed MSI by polymerase chain reaction (PCR) analyzing five nucleotide repeats (mono nucleotide BAT25, BAT26 and dinucleotide D2S123, D5S346, D17S250) and cases with at least two markers of instability were defined as MSI-H, (while cases with only one markers of instability were classified as MSI-L and no markers as MSS). The third study performed MSI analysis using a panel of three mononucleotide (BAT25, BAT26, and CAT25) and cases were divided in MSI-H (instability in two or three of the markers) and MSS if one only or no markers of instability. In addition, this study also performed the immunohistochemical staining of MMR proteins (MLH1, PSM2, MSH2, MSH6).

Outcomes
Clinical outcomes analyzed in the studies were heterogenous: 17 studies performed analyses on overall survival (OS), relapse-free survival (RFS), and disease-free survival (DFS), seven studies assessed rates of response to treatment, including radiological or pathological tumor responses (in four cases by RECIST criteria, the others using Becker, Mandard, and Japanese criteria of response).8,14,20,24,26,28,29 Three studies created a nomogram, stratifying patients according to biomarker results. Looking specifically at 17 studies which analyzed survival outcomes, half determined only OS and half both OS and DFS. In detail, the correlation between biomarker and survival has been performed on both pre- and post-NAC specimens in two studies (12.5%), on surgical samples post-NAC in four studies (4/16, 25%) while the majority of studies (n = 10) analyzed pre-NAC samples only (10/16, 62.5%). However, among these latter, only three studies, representing one sixth of the total selection, investigated tissue molecular biomarkers, whereas the vast majority looked at circulating biomarkers. Conversely, studies conducted on surgical samples analyzed mainly tissue biomarkers.

Specifically, retrospective studies conducted on MSI showed similar results with higher rate of RFS and OS for MSI-H subpopulation (RFS 21.4 months for MSS versus not reached for MSI-H patients, OS 38.6 months versus not reached in the MSI-H group).18 However, one study analyzed MSI on endoscopic pre-NAC samples and in this case, the presence of an
| Author | Study (Retro/Pros) | Country | Age (median) | Male (%) | Intestinal histotype (%) | G3 (%) | Clinical stage (cN+ or pN+) | Pathological stage (pN+) | Her2 positive (%) | Chemotherapy |
|--------|------------------|---------|--------------|----------|-------------------------|--------|---------------------------|------------------------|----------------|--------------|
| Grosser et al. | R | Europe | 60.9 | 70.2 | 74.4 | 59.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | R | Asia | 56.6 | 77.7 | 34.1 | 66.8 | NA | 42.9 | NA | Cisplatin + 5-FU |
| Catenacci et al. | R | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | R | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | R | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | P | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | P | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | P | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | P | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | P | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |
| van Hootegem et al. | P | Europe | 62.8 | 88.4 | NA | 69.0 | NA | 69.2 | NA | Cisplatin + 5-FU |
| Li et al. | P | Asia | 66.2 | 65.5 | 31.4 | 68.6 | NA | 62.9 | NA | SOX/XELOX |
| Catenacci et al. | P | USA | 66.6 | 78.8 | 33.3 | 72.2 | 75 | 47.0 | 16.7 | FOLFIRINOX |
| Qin et al. | P | Asia | 57.6 | 69 | 22 | 72.2 | NA | 47.0 | NA | Cisplatin + 5-FU |

5-FU, 5-fluorouracil; DCF, docetaxel, cisplatin and 5-FU; ECF, epirubicin, cisplatin, 5-FU; ECX, epirubicin, cisplatin and capcitabine; FLO, fluorouracil, leucovorin, cisplatin and panitumumab; FLOX, fluorouracil, leucovorin, oxaliplatin; NA, not available; P, prospective; R, retrospective; SOX, S-1 and oxaliplatin; XELOX, oxaliplatin and capecitabine.
Table 2. Biomarkers and outcomes of studies included in the review.11–33

| Author                | Biomarker                  | Endoscopic (E)/surgical (S) samples | N° cases (E/S) | Sample          | Method               | Outcome | Results                                                                 |
|-----------------------|----------------------------|-------------------------------------|----------------|-----------------|----------------------|---------|-------------------------------------------------------------------------|
| Gross et al.12         | p53 and correlation with MSI and EBV | Y/Y                                 | 138/294        | Tissue          | IHC, NGS             | OS      | p53 (surgical), p53 correlation with MSI/EBV                            |
| Li et al.8             | WES                        | Y/Y                                 | 35/35          | Tissue          | NGS                  | ORR     | C10orf71mut, MDM2 amplification MYC amplification                      |
| Catenacci et al.13     | UGT1A1                     | N/Y                                 | –/36           | Blood           | Liquid chromatography | OS, DFS | /                                                                        |
| Qin et al.14           | IgG glycomics profiling    | Y/Y                                 | 49/49          | Blood           | Liquid chromatography | ORR     | Glycans G4, G6, G18 Others GP                                           |
| van Hootegem et al.25  | NLR                        | Y/N                                 | 139/–          | Blood           | Flow cytometry       | OS, DFS | NLR                                                                     |
| Yeh et al.16           | ERCC1, ERCC2, XRCC        | N/Y                                 | –/58           | Tissue          | IHC                  | ORR, OS, DFS | ERCC1, ERCC2 XRCC                                                        |
| Chen et al.17          | PLr                        | Y/N                                 | 91/–           | Blood           | Flow cytometry       | OS, DFS | PLR (high plt count) PLR (low plt count)                                |
| Haag et al.18          | MSI                        | N/Y                                 | –/101          | Tissue          | IHC                  | OS, DFS | MSI-H /                                                               |
| Kohlruss et al.33      | MSI, EBV                   | Y/Y                                 | 143/326        | Tissue          | PCR                  | ORR, OS | MSI-H, EBV+ for OS in resected non-CTx cohort MSI-H, EBV+ for response to CT and OS in biopsy cohort |
| Smyth et al.19         | CDH1, ELOVL5, EGFR, PIP5K1B, FGF1, CD44v8.10, TBCEIL [7-gene Signature] | N/Y | –/84 | Tissue | PCR | OS | High Risk (HR) versus Low Risk (LR) /                                  |
| Liu et al.20           | microRNA                  | Y/N                                 | 15/–           | Tissue          | PCR                  | ORR     | /                                                                       |
| Li et al.25            | CLR                        | Y/Y                                 | 112/112        | Blood           | Flow cytometry       | ORR, OS | High CLR versus Low CLR /                                               |
| Bozkaya et al.22       | Survinin                   | Y/N                                 | 50/–           | Blood           | PCR                  | ORR, OS, DFS | / Survinin                                                            |
| Stahl et al.23         | EGFR, HER2, MET            | N/Y                                 | –/160          | Tissue and blood | IHC, ISH/FISH        | OS, DFS | HER2+, MET EGFR                                                        |

(continued)
Table 2. (continued)

| Author       | Biomarker                                   | Endoscopic (E)/surgical (S) samples | N° cases (E/S) | Sample | Method | Outcome | Results                                      |
|--------------|---------------------------------------------|------------------------------------|----------------|--------|--------|---------|----------------------------------------------|
| Tan et al.24 | microRNA                                    | Y/N                                | 120/–          | Blood  | PCR    | ORR     | miR-145, miR-185                             |
|              |                                             |                                    |                |        |        |         | miR-381, miR-195                             |
| He et al.25  | T cell subpopulations                       | Y/N                                | 105/–          | Blood  | Flow cytometry | OS      | High CD3+CD8+ T cell longer OS               |
|              |                                             |                                    |                |        |        |         | CD3+CD4+ T cell                              |
| Li et al.26  | P-gp, GST, topo II, MRP, LRP, Ki-67, p53    | Y/N                                | 93/N           | Tissue | IHC    | ORR     | Ki-67, p53                                   |
|              |                                             |                                    |                |        |        |         | P-gp, GST, Topo II, MRP, LRP                 |
| Li et al.27  | MTHFR, DPYD UMPS, ABCB1, ABCC2, ERCC1, XRCC1, and GSTP1 polymorphism | Y/N                                | 103/N          | Blood  | PCR    | OS      | ABCC2-24C>T Others polymorphisms            |
| Qu and Qu28  | C-met, EGFR, HER2, Ki-67, MMP7, p53, Topo II| Y/Y                                | 53/53          | Tissue | IHC, FISH | ORR     | HER2, p53                                   |
|              |                                             |                                    |                |        |        |         | c-MET, EGFR, Ki-67, MMP7, topoll             |
| Jia et al.29 | DAP-3                                       | N/Y                                | ~85            | Tissue | IHC, PCR | ORR     | DAP-3                                        |
| Hirakawa et al.30 | ERCC1, DDB2                              | Y/N                                | 43/–           | Tissue | IHC    | OS, DFS | ERCC1, DDB2                                 |
| Mutze et al.31 | DNMT1, DNMT3b                              | Y/N                                | 127/–          | Tissue | IHC    | OS      | DNMT1, DNMT3b                               |
| Ott et al.32 | TS, MTHFR                                   | N/Y                                | ~135           | Blood  | PCR    | OS      | TS 2rpt/2rpt, TS 2rpt/3rpt, TS 3rpt/rpt     |

CDH1, cadherin-1; CLR, circulating lymphocyte ratio; DAP3, death-associated protein 3; DDB2, DNA damage-binding protein 2; DPYD UMPS, dihydropyrimidine dehydrogenase; DNMT1/3b, DNA cytosine-5-methyltransferase 1/3b; EBV, Epstein-Barr Virus; EGFR, epidermal growth factor receptor; ERCC1/2, DNA excision repair protein ERCC-1/2; ELOVL5, elongation of very long chain fatty acids protein 5; FGFI, fibroblast growth factor 1; GST, glutathione-S-transferase; HER2, human epidermal growth factor receptor 2; IgG, immunoglobulin G; LRP, low density lipoprotein receptor related protein 1; MMP7, matrix metalloproteinase 7; MRP, MARCKS-related protein; MSI, microsatellite instability; MTHFR, methylene tetrahydrofolate reductase; NLR, neutrophil-lymphocyte ratio; P-gp; P-glycoprotein; PIP5K1B, phosphatidylinositol 4-phosphate 5-kinase type-1; PLR, platelet-lymphocyte ratio; TBC, tubulin-specific chaperone cofactor E-like; UGT1A1, UDP glucuronosyltransferase 1 family, polypeptide A1; WES, whole exome sequencing.
aberrant p53 expression was associated with a worse OS in the MSI-H subgroup even compared to MSS/EBV negative (median MSI-H 23.4 months, MSS/EBV= 36.6 months), potentially losing the positive prognostic effect of MSI-H.8 Thymidylate synthase (TS) tandem repeat polymorphism analyzed in blood samples has been identified as independent prognostic factors in the NAC group, with a significant survival benefit for the 2rpt/2rpt (p = 0.002) and 2rpt/3rpt genotypes (p = 0.004).32 Regarding response to NAC, multi-omics characterization and RNA sequencing on tumor tissues allowed to identify C10orf71 mutations that were associated with treatment resistance (p = 0.00011) as well as MDM2 (p = 0.033),8 while MYC amplification correlated with treatment sensitivity. Similarly, polymorphisms in genes involved in drug metabolism has been associated with NAC response: for example, patients with TT and TC genotypes of ABCC2-24C > T (rs717620) responded to NAC 3.80 times more often than those with the CC genotype.27 Outcomes of studies included in the review are summarized in Table 2.

Discussion

The identification of predictive biomarkers for NAC in radically resectable locally advanced gastric and EGJ cancer is an unmet clinical need. Tissue-derived or circulating biomarkers have been widely studied, but these data are hardly applicable to the curative setting at the time being.11 Starting from that, we searched the literature for articles investigating biomarkers in LAGC and 23 articles were finally included in our review.12–33 The population evaluated in the analysis was homogeneous in terms of clinical setting, since all patients had a gastric or EGJ cancer, received NAC, and underwent radical surgery. The main characteristics of the population were well balanced among the different studies, with a slight predominance of Asiatic patients, since 13 studies out of 23 were conducted in Eastern countries. Similarly, NAC was consistent across the selection: fluoropyrimidines were the common denominator of the various regimens, with limited differences related to standard of care. In this setting, clinical practice varies between geographical areas, mainly due to differences in tumor characteristics and local preferences. While perioperative chemotherapy is the preferred strategy in Europe, adjuvant chemotherapy is preferred in Asia and adjuvant chemo(radio)therapy in US.34–36 Conversely, we observed a high heterogeneity in the evaluated biological samples (blood, biopsy specimen, surgical specimen), in the types of biomarkers tested, utilized methods and analyzed clinical outcomes. Circulating biomarkers derived from liquid biopsy (LB) have potentially a great role in gastric and EGJ cancer where molecular characterization usually relies on a single or a few endoscopic biopsies in the pre-operative setting, sometimes even inadequate for complete molecular characterization. Research conducted in solid tumors showed promising results about feasibility and relevance of LB to detect predictive biomarkers in colorectal and lung cancer.37,38 In gastric and EGJ cancer, LB research is in its beginnings, and only few studies looked at the correlation between HER2 amplification in plasma and in histological samples.39,40 Our review included 11 papers analyzing circulating biomarkers looking prevalently at blood count ratio or gene polymorphisms involved in chemotherapy metabolism. Some results are encouraging, but prospective trials conducted in larger populations are needed.

Microsatellite instability (MSI) is one of the most studied biomarkers in solid tumors, including gastric cancer. In early-stage colorectal cancer, it is associated with a lack of benefit from adjuvant chemotherapy,41 and its determination is now clinical practice to tailor adjuvant treatment decision in stage II. Similarly, MSI impact on outcomes was tested in resected gastric cancer. Pietrantonio and colleagues8 performed an individual patient data meta-analysis from the MAGIC, CLASSIC, ARTIST, and ITACA-S trials showing statistically significant longer 5-year OS rate for MSI-H group compared to MSI-low and MSS (77.5% versus 59.3%). Moreover, the addition of chemotherapy was beneficial for MSI-low/MSS GC (5-year DFS of 57% versus 41% with surgery alone), in contrast with the MSI-H subgroup (70% versus 77%). These results support the use of MSI as prognostic marker for resectable gastric cancer. However, the meta-analysis included trials assessing mainly adjuvant chemotherapy, as well as patients who received chemoradiation1,42–44 with only less than 10% of the whole dataset treated with NAC and analyzed for MSI status. Furthermore, no pre-NAC biomarkers evaluation was reported. As a result, it appears premature to translate these findings into clinical decision making about NAC. Three studies included in our review looked at MSI status confirming the positive prognostic value of this marker. Two of them checked the
MSI both pre- and post-NAC, essential and mandatory to get solid information on prediction to NAC response and survival benefit.

Programmed death ligand-1 (PD-L1) status is emerging as a predictive factor of response to immunotherapy. After first FDA approval for pembrolizumab and nivolumab in advanced lines, negative results of subsequent studies highlighted the necessity of identify which patient will benefit from these agents. Currently, a combined positive score (CPS) greater than or equal to one identifies PD-L1 positive tumors, even though first line CHECKMATE-649 just presented at ESMO 2020 looked specifically to CPS\(\geq 5\) population, showing an increase OS of 3.3 month (median) with the addition of nivolumab to chemotherapy. However, in our review, no study did analyze PD1/PD-L1 status, likely due to the lack of immunotherapy in the peri-operative setting at the time being.

Our study presents several limitations: first, the heterogeneity of biomarkers analyzed and utilized methods, which prevents from performing statistical analyses. Secondly, patients enrolled in the chosen studies display important epidemiologic differences (with regard to ethnicity, age, etc) resulting in biological diversity, as well as great dissimilarities in the administered chemotherapy regimens. Thirdly, different clinical outcomes, different time points of the biomarkers evaluation, and different correlations increased the risk of biases in interpreting general results from this analysis. Lastly, we arbitrarily chose to focus only on biological biomarkers, excluding imaging. For instance, 18-fluorodeoxyglucose-PET (PET) has shown promising results in response prediction in the neo-adjuvant setting of EGJ cancers. On the other side, a potential strength of our review is the focus on only locally advanced radically resectable gastric and EGJ adenocarcinoma treated with NAC. Moreover, a considerable number of studies included in our review assessed biomarkers on pre-NAC samples, which is the best approach for the implementation of predictive markers, and closest to the setting needed for clinical practice.

In conclusion, our review showed a high heterogeneity in investigating prognostic and predictive biomarkers for NAC in gastric and EGJ cancer, particularly due to the type of biomarker, type of sample used, methods of detection, timing of evaluation and, lastly, clinical endpoints correlated. Therefore, for all these aspects, our results cannot be considered conclusive but just descriptive. However, some insights could be drawn as hypothesis-generating. Even though MSI is, among all the investigated biomarkers, the one with the potentially highest clinical impact, any study of our analysis reported a solid and strict correlation with NAC. In fact, there are reports about the potential detrimental effect of chemotherapy for MSI-H gastric cancer, but data are deduced comparing MSI-H with MSS tumors and a specific study on solely MSI-H gastric cancer treated or not with chemotherapy has not been performed. Moreover, one study presented a challenging negative interaction of aberrant p53 with MSI-H, although number of patients is limited. This data deserves to be specifically investigated in future well-designed clinical trial addressing NAC in radically resectable locally advanced EGJ and gastric cancer. Furthermore, some enzymatic biomarkers, as TS, UGT1A1, MTHFR, ERCC, or XRCC, raised as promising predictive factors of NAC in several studies of our analysis, suggesting that it could be useful their determination for tailoring the therapeutic algorithm and, lastly, to include them in future studies on NAC in EGJ and gastric cancer, always with uniform techniques and a consistent timing.

Conflict of interest statement

FLorian Lordick declares COI for: Amgen Advisory Board Astellas Advisory Board Astra Zeneca Invited Speaker Bayer Advisory Board Beigene Advisory Board Biontech Expert Testimony BMS Invited Speaker BMS Advisory Board BMS Expert Testimony Eli Lilly Invited Speaker Eli Lilly Advisory Board Elsevier Expert Testimony Imedico Writing Engagement Medscape Invited Speaker MedUpdate Invited Speaker Merck Serono Invited Speaker MSD Advisory Board MSD Invited Speaker MSD Advisory Board MSD Expert Testimony Roche Invited Speaker Roche Advisory Board Promedicis Invited Speaker Servier Invited Speaker Servier Advisory Board Springer-Nature Writing Engagement StreamedUp! Invited Speaker Zymeworks Advisory Board Imedex Invited Speaker Deutscher Ärzteverlag Writing Engagement Nicola Fazio declares COI for Novartis Consulting and advisory services, speaking engagements, Steering committee Ipsen Consulting and advisory services, speaking engagements, Steering committee Pfizer Advisory services Merck Serono Advisory services, Speaking engagements Advanced Accelerator Applications Advisory
services MSD Advisory services Sanofi-Aventis Speaking engagements ACCMED Speaking engagements Wren Laboratories Europe Advisory services EANM Advisory services Springer Writing engagements Pensiero Scientifico Editore Writing engagements All other authors declare no COIs.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Lorenzo Gervaso https://orcid.org/0000-0003-3313-8527

References
1. Cunningham D, Allum WH, Stennin SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.
2. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715–1721.
3. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948–1957.
4. Fazio N, Biffi R, Maibach R, et al. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. Ann Oncol 2016; 27: 668–673.
5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202–209.
6. Kim Y, Cho M-Y, Kim J, et al. Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. Oncotarget 2017; 8: 69888–69905.
7. Sohn BH, Hwang J-E, Jang H-J, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. Epub ahead of print 26 July 2017. DOI: 10.1158/1078-0432.CCR-16-2211.
8. Li Z, Gao X, Peng X, et al. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv 2020; 6: eassy4211.
9. Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019; 37: 3392–3400.
10. Naseem M, Barzi A, Brezden-Masley C, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 2018; 66: 15–22.
11. van den Ende T, Ter Veer E, Mali RMA, et al. Prognostic and predictive factors for the curative treatment of esophageal and gastric cancer in randomized controlled trials: a systematic review and meta-analysis. Cancers (Basel) 2019; 11: 530.
12. Grosser B, Kohlruss M, Slotta-Huspenina J, et al. Impact of tumor localization and molecular subtypes on the prognostic and predictive significance of p53 expression in gastric cancer. Cancers (Basel) 2020; 12: 1689.
13. Catenacci DVT, Chase L, Lomnicki S, et al. Evaluation of the association of perioperative UGT1A1 genotype-dosed gFOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally advanced gastroesophageal adenocarcinoma: a phase 2 clinical trial. JAMA Netw Open 2020; 3: e1921290.
14. Qin R, Yang Y, Chen H, et al. Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling. Clin Proteomics 2020; 17: 4.
15. van Hootegem SJM, Smithers BM, Gotley DC, et al. Baseline neutrophil-lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. Dis Esophagus 2020; 33: doz082.
16. Yeh YS, Chen YT, Tsai HL, et al. Predictive value of ERCC1, ERCC2, and XRCC expression for patients with locally advanced or metastatic gastric cancer treated with neoadjuvant mFOLFOX-4 chemotherapy. Pathol Oncol Res 2020; 26: 1105–1116.
17. Chen L, Hao Y, Cong X, et al. Peripheral venous blood Platelet-to-Lymphocyte Ratio (PLR) for predicting the survival of patients with gastric cancer treated with SOX or XELOX regimen...
neoadjuvant chemotherapy. Technol Cancer Res Treat 2019; 18: 153303819829485.

18. Haag GM, Czink E, Ahadova A, et al. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer 2019; 144: 1697–1703.

19. Smyth EC, Nyamundanda G, Cunningham D, et al. A seven-gene signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann Oncol 2018; 29: 2356–2362.

20. Liu X, Cai H, Sheng W, et al. microRNAs expression profile related with response to perioperative radiochemotherapy in patients with locally advanced gastric cancer. BMC Cancer 2018; 18: 1048.

21. Li Y, Wei Y, He Q, et al. Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Sci Rep 2018; 8: 6223.

22. Bozkaya Y, Özdemir NY, Sezer S, et al. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy? Cancer Biomark 2018; 22: 143–149.

23. Stahl M, Maderer A, Lordick F, et al. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). Eur J Cancer 2018; 93: 119–126.

24. Tan B, Li Y, Di Y, et al. Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer. J Clin Lab Anal 2018; 32: e22363.

25. He Q, Li G, Ji X, et al. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Tumour Biol 2017; 39: 1010428317697571.

26. Li S, Li B, Wang J, et al. Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction. Oncol Res 2017; 25: 93–97.

27. Li Z, Xing X, Shan F, et al. ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget 2016; 7: 55449–55457.

28. Qu J and Qu X. The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer Biomark 2016; 17: 49–54.

29. Jia Y, Ye L, Ji K, et al. Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. Br J Cancer 2014; 110: 421–429.

30. Hirakawa M, Sato Y, Ohnuma H, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: Nucleotide Excision Repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol 2013; 71: 789–797.

31. Mutze K, Langer R, Schumacher F, et al. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur J Cancer 2011; 47: 1817–1825.

32. Ott K, Vogelsang H, Marton N, et al. The thymidylate synthase tandem repeat promoter polymorphism: a predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 2006; 119: 2885–2894.

33. Kohlruss M, Grosser B, Krenauer M, et al. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability. J Pathol Clin Res 2019; 5: 227–239.

34. Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by GSCO, KSMO, MOS, SSO and TOS. Ann Oncol 2019; 30: 19–33.

35. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl. 5): v38–v49.

36. National Comprehensive Cancer Network Guidelines. Gastric cancer. Version 3. Plymouth Meeting, PA: National Comprehensive Cancer Network Guidelines, 2020.

37. Grasselli J, Elez E, Caratù G, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in
metastatic colorectal cancer. *Ann Oncol* 2017; 28: 1294–1301.

38. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. *Ann Oncol* 2015; 26: 698–710.

39. Shoda K, Masuda K, Ichikawa D, et al. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. *Gastric Cancer* 2015; 18: 698–710.

40. Shoda K, Ichikawa D, Fujita Y, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. *Gastric Cancer* 2017; 20: 126–135.

41. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol* 2010; 28: 3219–3226.

42. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012; 379: 315–321.

43. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2012; 30: 268–273.

44. Bajetta E, Floriani I, Di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. *Ann Oncol* 2014; 25: 1373–1378.

45. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 390: 2461–2471.

46. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol* 2018; 4: e180013.

47. Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2018; 392: 123–133.

48. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN gastric 300. *Ann Oncol* 2018; 29: 2052–2060.

49. Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastriccancer/gastroesophageal junction cancer (GC/GEJC)/Esophageal Adenocarcinoma(EAC): first results of the CheckMate 649 study. *Ann Oncol* 2020; 31(Suppl. 4): S1142–S1215.

50. Schneider PM, Eshmuminov D, Rordorf T, et al. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardio cancer: cohort study. *BMC Cancer* 2018; 18: 548.

51. Ratti M, Lampis A, Hahne JC, et al. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. *Cell Mol Life Sci* 2018; 75: 4151–4162.